Neural precursor cells (NSCs) hold great potential to treat a variety of neurodegenerative diseases and injuries to the spinal cord. However, current delivery techniques require an invasive approach in which an injection needle is advanced into the spinal parenchyma to deliver cells of interest. As such, this approach is associated with an inherent risk of spinal injury, as well as a limited delivery of cells into multiple spinal segments.
A direct parenchymal injection of cells is the most frequently used technique and was successfully used in both rodent and large animal models. [1] [2] [3] [4] [5] [6] In some of these studies, a statistically significant neuroprotective effect (as defined by the recovery of motor function and decreased neuronal degeneration) was demonstrated providing a rationale for further preclinical development of cell-replacement therapies for ALS and SCI. 2, 3, 5, 6 An intrathecal cell delivery was also used to test the treatment potency of neural precursors in rat spinal trauma model. 7 In recently completed and ongoing clinical trials, an invasive cell delivery technique that requires direct needle penetration into the spinal parenchyma is used to deposit cells into the specific spinal target (such as the ventral horn gray matter). [8] [9] [10] Although effective in delivering cells into the spinal parenchyma, the invasive nature of this approach limits the number of injections that can be performed. Accordingly, this celldelivery approach is not effective in achieving trans-spinal occupation by grafted cells. This limitation can be of significant importance, particularly in the treatment of spinal neurodegenerative diseases characterized by multisegmental degeneration (such as spinal traumatic injury) or panneuronal degeneration (as seen in inherited or sporadic forms of ALS).
Because of safety concerns, the current clinical protocols for cell delivery only employ regional cell injections (cervical and lumbar enlargements in ALS) or peri-injury injections (in case of spinal trauma).
In a recently completed phase II dose-escalation ALS trial, a maximum of 20 cell injections of human fetal neural precursor cells (hNSCs) (NSI-566) were delivered at lumbar and cervical levels of the spinal cord. 9 The highest total cell dose delivered in a single patient was 16 million, and covered a region of approximately 8 cm length. Considering the length of the spinal cord in adult humans is approximately 50 cm, this 8 cm region represents only a portion of spinal cord gray matter mass which can potentially benefit from regional cell replacement therapy. In an ongoing phase I trial for the treatment of chronic SCI with spinal injections of fetal hNSCs, a total of six injections are being delivered around the injury epicenter (10 μl each, 200 000 cells/ injection). 11 In a second completed phase I subacute spinal trauma trial, human embryonic stem cell-derived oligodendrocyte precursors (AST-OPC1) were injected (2 million cells) at a single site 5 mm caudal to the injury epicenter. In another ongoing AST-OPC1 dose-escalation study, the maximum cell dose planned is 20 million cells delivered as a single injection. 10 The primary rationale for using OPCs as a cell-based therapeutic in spinal trauma is to accelerate local remyelination and promote/restore axonal conductivity. It is expected that the ability to achieve rapid and multisegmental delivery of OPCs will likely be associated with a more pronounced therapeutic effect.
As described, the use of a limited number of direct parenchymal cell injections represents a key limiting factor in achieving multisegmental cell repopulation in spinal cord treatment protocols. Accordingly, the development of a safer and more effective spinal cell delivery technique to achieve rapid and multisegmental spinal cord repopulation by injected cells would represent a significant improvement over the currently available protocols. Recently, we have described a novel subpial AAV9 delivery technique and demonstrated robust multisegmental transgene expression in adult pigs, rats, and mice. 12, 13 We have also demonstrated that the pia mater represents the primary barrier that limits vector penetration into the deep spinal parenchyma. To our knowledge, the use of the subpial space as a potential route for spinal cell delivery has not been explored.
In our current study, we analyzed the survival, rostrocaudal migration and differentiation profile (neuronal and glial differentiation) of hNSCs at 6-8 months after subpial delivery in immunodeficient rats. We demonstrate that spinal subpial injection leads to the near complete occupation of the entire rat spinal cord by injected hNSCs at 6-8 months after cell delivery. In addition, a recently developed human-specific mRNA sequencing protocol that differentiates human from rat transcripts was used to characterize the gene expression profile of subpially injected hNSCs. No neurologically defined side effects (motor or sensory) or tumor formation was seen in any animal. These results represent a significant advance in the effort to develop a more efficient cell-delivery system for the treatment of spinal cord neurodegenerative disorders.
| METHODS
All procedures were approved by the Institutional Animal Care and Use Committee by the University of California, San Diego (Protocol No.: S01193). All studies were performed in such a manner as to minimize group size and animal suffering. Adult Sprague-Dawley immunodeficient rats (Crl:NIH-Foxn1rnu; Charles River) male and female, 250-350 g; (n = 6) were used in this study.
| Placement of subpial cell-injection needle
Rats were anesthetized with 5% isoflurane and maintained at 2%-3% isoflurane during surgery depending on breathing rate and paw pinch response. The back of the rat was then shaved and cleaned with 2% chlorhexidine. After skin incision, the paravertebral muscle surrounding the cervical and lumbar spinal vertebrae was removed and animals were mounted into a spinal immobilization frame (Stoelting) using Cunningham's spinal clamps, as previously described. 14 was performed using a dental drill. The dura was then cut open using a scalpel blade or 30G needle.
To inject cells into the subpial space, two sequential procedural steps that used two independent XYZ manipulators (Supporting Figure S1A ,B) were used. From the time point of dura exposure, all subsequent manipulations were performed under a dissecting scope with ×5-10 magnification. First, a 33G pia-puncturing needle with the tip bent at 90 and mounted on the Z arm was used to puncture the pia ( Figure S1C ). The puncturing needle was previously sharpened using a glass capillary beveller (Pipet Micro Grinder EG-40; Narishige)
with Diamond abrasive plate-coarse (5.0-50 μm tip sizes). After the pia was punctured, the puncturing needle was removed. In the majority of cases, the site of the punctured pia is easily recognizable even if the puncturing needle is removed. Second, a blunt 33G needle mounted on the second Z arm was then advanced into the subpial space through the pia opening. The needle was advanced into the subpial space for approximately 4-6 mm ( Figure S1D ,E). For demonstration purposes, contrast (Evans blue) was injected in the pilot experiment to demonstrate the spread of subpially injected solution.
As shown in Figure S1F , a clear spread of contrasted solution in the ipsilateral subpial space can be seen immediately after injection.
| Source, preparation, and injection of hNSCs into the subpial space
The human cortical NSC lines (NSI-HK532) were provided by Neuralstem, Inc. (Germantown, Maryland, http://www.neuralstem. com). Briefly, HK532 were prepared from cortical tissue obtained from a single 8-week-old human fetus following an elective abortion, as previously described. 15 The material was donated to Neuralstem, Inc. with informed consent in a manner compliant with guidelines of the National Institutes of Health and the FDA, and according to guidelines that were reviewed and approved by an outside independent review board.
Cells used for transplantation were harvested as an undifferentiated nestin-immunopositive population. In our current study, stably GFPexpressing cells prepared by lentiviral infection of HK532 line with HIV1-UBI-GFP vector were used. Previously cryopreserved cells were thawed, washed, and resuspended in hibernation media at a concentration of 80 000/μl. Cells were delivered into the subpial space through the previously subpially placed 33G needle interconnected to a digital microinjector at a rate of 1 μl/s. A total of 20 μl of cell suspension was delivered at each C2-C3 and Th12-L1 subpial site in each animal (ie, total of 40 μl/animal; total of 3.2 million cells).
In order to analyze the differentiation of HK532 and HK-532-UBI-GFP in vitro, cells were grown to confluence and the media was changed to medium lacking growth factors to initiate differentiation. 15 After 10 days, cells were fixed in 4% paraformaldehyde and immunostained using neuron-specific and glia-specific markers (see Immunofluorescence Staining; Table 1 ).
| Analysis of motor and sensory function
The effect of combined cervical and lumbar subpial cell delivery on neurological function was analyzed in all animals (6 rats) in 14-day intervals for 6 months. Open field locomotion testing: changes in motor function was assessed using a Basso, Beattie, Bresnahan open field 21 grade locomotion rating scale. 16 The presence of allodynia was tested by presence/absence of vocalization/withdrawal from touching the trunk around the level of subpial cell delivery with a 20 g von Frey filament. Sections were then stained with neuron-specific or glia-specific primary antibodies (Table 1) using the previously reported staining protocol. 5 Then, staining sections were mounted on slides, dried at room temperature, and covered with a Prolong anti-fade kit (Invitrogen). In vitro-induced and 4% paraformaldehyde-fixed hNSCs were stained using neuron or glia-specific primary antibodies (Table 1) .
Fluorescence images were captured using a Zeiss Imager M2 microscope and confocal images were taken using an Olympus FV1000 microscope. Single-end 75 bp reads (Illumina HiSeq4000) were received in FASTQ format and were prepared for downstream analysis by trimming known barcodes and then selecting post-trimmed reads for those with average base quality >15. Following the previously described preprocessing steps, 17 reads were aligned with HISAT2 to a combined rat (Rn6) and human (Hg38) genome index. We used -k 20 and-scoremin L,0,-0.4 with otherwise default settings. Aligned reads were sorted by read name and then evaluated for species of origin with an in-house perl script. The vast majority of reads only aligned to a single genome, but for those that aligned to both genomes we used the HISAT2 alignment score to guide species assignment. If a read mapped equally well to both genomes then it was flagged as ambiguous and excluded from downstream analysis. Otherwise the read was assigned to the species for which it has the best alignment score.
| Quantification of subpially injected hNSCs
Species assigned reads were quantified using Kallisto. Human reads were quantified against the full Gencode annotation (v28) and rat assigned reads were quantified against the Refgene annotation for the Rn6 genome (obtained from the UCSC Genome Browser). Kallisto A higher proportion of GFP+ cells was seen in white matter as compared to gray matter in the same region ( Figure 1G ).
Analysis of sagittal brain sections showed extensive cell migration into the medulla oblongata, brain stem, and white matter tracts of the cerebellum ( Figure 1H Figure S4A ,B.
| Injected hNSCs-derived astrocytes mature and acquire morphological and phenotypic characteristic of glia limitans-forming endogenous astrocytes
Using higher power imaging and confocal microscopy, we next studied the detailed localization and phenotype of GFP+ cells. First, using horizontally cut sections, a multilayer of GFP+ cells was consistently seen in the subpial space across multiple spinal segments rostral and caudal to the cell injection sites (Figure 2A,E) . Similarly, co-staining with endothelial marker (Reca-1) showed a clear presence of GFP+ cells in the subpial-perivascular space (Figure 2A) . Second, to probe for the contribution of the GFP+ cells to formation of glia limitans, sections were stained with human-specific and nonspecific (ie, cross-reacting with rat and human) anti-GFAP antibody. The glia limitans (also called glial limiting membrane or lamina limitans) is the outermost layer of spinal neural tissue and is composed of astrocytes and their foot processes. The primary function of the glia limitans is the prevention of the migration of neurons and neuroglia into the meninges and restriction of the entry of inflammatory cells and small molecules into the brain and spinal parenchyma. 18, 19 In the analyzed sections, numerous GFP+ cells were found (a) between the pia mater and glia limitans, (b) to be and acquired the morphological phenotype that appears to be identical to this specialized glia limitans-forming endogenous astrocytes.
One of the protective mechanisms of the glia limitans is its role in suppressing/modulating the effect of oxidative stress. Glia limitansforming astrocytes have been reported to selectively express the superoxide dismutase (SOD). 20 SOD expression is not seen in parenchymal astrocytes. 8 Therefore, we next tested if the hNSC-derived astrocytes in the glia limitans also overexpressed SOD. As shown in Figure 2F ,G, a high level of SOD expression was seen throughout the glia limitans with numerous GFP+ and human-specific GFAPexpressing astrocytes and their processes expressing the SOD.
Another protective mechanism associated with the function of glia limitans-forming astrocytes is its contribution to the formation of the parenchymal basal membrane by synthesis of laminin. 21 We have therefore stained spinal cord sections with human-specific laminin Figure S5A ).
The same immunofluorescence analysis of GFP+ cells residing in the gray matter showed that the majority of GFP+ cells were Olig2 or vimentin positive ( Figure 3B and Figure S5B ). Only occasional hGFAP+ cells were identified in the gray matter; these hGFAP astrocytes were typically found at the border between the white and gray matter ( Figure 3D , inset). Staining with Ki67 (marker of mitotically active cells) antibody showed only occasional presence of GFP/Ki67+ cells in both the white and gray matter ( Figure S5F,G) . Quantitative analysis of double-stained GFP/Olig2+, GFP/hGFAP+, GFP/Ki67+, and GFP/vimentin+ cells in the white and gray matter is presented in Table 2 .
One of the functions of CNS astrocytes is the control of extracellular glutamate concentration. It is mediated by the activity of membrane-bound glutamate transporters (GLAST, GLT1). 22 It was demonstrated that the loss or altered function of these transporters can lead to progressive neuronal degeneration (such as seen in ALS)
as a result of excessive glutamate receptor activation. 23, 24 To study if the human astrocytes express GLAST, sections were stained with a combination of hGFAP and GLAST antibodies. A highly specific GLAST expression was seen in both the glia limitans-forming human astrocytes as well as in the protoplasmic human astrocytes found in the deeper white matter ( Figure 3E-H ).
| Transcriptome analysis of subpially injected NSCs
We next performed mRNA sequencing on the subpially hNSC-injected spinal cord tissue, and used a previously developed bioinformatics method to separate human and rat transcripts from the mixed-species graft 17 ( Figure 4A ). Using this protocol, the analysis of brain stem, cervical, thoracic, and lumbar spinal cord revealed the consistent presence of human-specific transcripts ( Figure 4B ). mRNA transcript analysis demonstrated the preferential upregulation of astrocyte-specific (GFAP, ALDH1L1, AQP4, ALDOC) and oligodendrocyte-specific (MBP, CLDN11) genes, but minimal neuronal transcripts ( Figure 4C ). In addition, a clear high level expression of SOD1 and LAMB2 (lamininassociated gene) genes was seen ( Figure 4D ). These results support our observations from immunofluorescence staining, and confirm the preferential differentiation of the grafted hNSCs into glial cells as well as high level of SOD1 protein and human-specific laminin expression in glia limitans-forming human astrocytes. There was no evidence of microglial differentiation in the graft tissue, as microglia do not originate from neural precursors. Furthermore, although NSC genes were still expressed by the grafted cells, there was no evidence of pluripotencyassociated gene (NANOG, POU5F1) expression ( Figure 4C ).
| Animals injected subpially with hNPCs show normal neurological function and no tumor formation
Assessment of neurological motor function 25 
| Mechanisms of cell migration into the spinal parenchyma after subpial cell delivery
The pia mater is the innermost layer of the meninges, and is composed of fibroblasts that ensheath the entire length and surface of the spinal Note: Data are expressed as percentage of double-stained GFP/Olig2, GFP/hGFAP, GFP/Ki67, and GFP/Vimentin cells relative to total number of GFP+ cells.
cord. The glia limitans (glia limiting membrane or lamina limitans) is a thin layer/barrier of GFAP+ astrocytes on the surface of the spinal cord and brain, and is associated with parenchymal basal lamina. 18, 19 Analysis of injected GFP+ cells showed that many of the subpial-injected GFP+ cells effectively incorporated into the glia limitans. In addition, histological-morphological analysis and staining with SOD and humanspecific laminin antibodies showed that the hNSC-derived human astrocytes acquired morphological and functional characteristics that are typical of glia limitans-forming endogenous astrocytes. These were characterized by the presence of a high density of human astrocytederived foot processes, contributing to the formation of glia limitans, and expression of SOD and synthesis of human-specific laminin, contributing to the formation of the basal membrane. Previous studies have demonstrated that a direct physical contact between pia-forming fibroblast and astrocytes is the primary trigger initiating astrocyte-derived laminin synthesis. 21 Accordingly, we speculate that a direct interaction of subpially injected hNSCs with the pial membrane is the mechanism leading to laminin synthesis by terminally differentiated hGFAP+ astro- These data also suggest that the spinal white matter lacks the necessary neuronal induction signals, and further suggests the existence of a highly specific and potent regulatory mechanism which controls astrocyte vs oligodendrocyte differentiation in white vs gray matter.
This interpretation is consistent with several previous studies that show a high degree of neuronal differentiation in the core of an hNSC spinal graft targeted to the gray matter, whereas a much higher density of glial cells is observed at the periphery of such grafts. Third, the pathology and corresponding neurological dysfunction associated with transverse myelitis is characterized by the loss of local oligodendrocytes and can simultaneously affect multiple segments. 27, 28 Thus, similarly as for spinal trauma, subpial delivery of OPS or hNSCs can be used to restore segmental myelination and function. Fourth, the use of cell-replacement-based therapies for the treatment of lysosomal storage disease by delivering genetically modified cells into the CNS can potentially benefit from the widespread cell repopulation achieved after subpial cell delivery. 29, 30 Finally, there is long lasting interest to employ autologous or allogeneic cells genetically modified to produce antinociceptive inhibitory neurotransmitters such as GABA for the treatment of chronic neuropathic pain. [31] [32] [33] By using a regional subpial injection of such cells, a regionally targeted release of GABA could be achieved and potentially lead to a long lasting, anti-nociceptive effect.
| Technical requirements to perform effective and safe subpial injection
In our previous studies, we have described the technique of subpial AAV9 vector delivery and identified the pia mater as the major barrier which limits the penetration of the AAV9 vector into the deep spinal parenchyma in mice, rats and pigs. 12, 13 Our original technique used subpial placement of a PE-5 or PE-10 catheter after the pia was punctured using a manually positioned 30G pia-penetrating needle. Our current technique was slightly modified with two XYZ manipulators mounted firmly on a spinal immobilization frame. This modification substantially simplified and improved the safety of the entire subpial cell injection procedure and can readily be used by any surgeon with established expertise to perform spinal laminectomy in rodents, large animal models (pigs, monkeys) or in humans.
